| Vinu Ninan, MD | |
|
14023 Southwest Fwy, Sugar Land, TX 77478-3550 | |
| (281) 325-4100 | |
| Not Available |
| Full Name | Vinu Ninan |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 14023 Southwest Fwy, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689106486 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hermann Sugar Land Hospital | Sugar land, TX | Hospital |
| Memorial Hermann Hospital System | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorial Hermann Medical Group | 7012008360 | 590 |
News Archive
Across the nation, states are grappling with alternative approaches to address the heightened problem of low nurse staffing in hospitals.
In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
One single molecule determines how stem cells in the hair follicle develop. A study at the Sahlgrenska Academy at Göteborg University in Sweden has shown that cells that should give rise to hair can instead give rise to mammary gland cells in mice who lack this molecule.
Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
› Verified 1 days ago
| Entity Name | Memorial Hermann Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003985102 PECOS PAC ID: 7012008360 Enrollment ID: O20070801000368 |
News Archive
Across the nation, states are grappling with alternative approaches to address the heightened problem of low nurse staffing in hospitals.
In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
One single molecule determines how stem cells in the hair follicle develop. A study at the Sahlgrenska Academy at Göteborg University in Sweden has shown that cells that should give rise to hair can instead give rise to mammary gland cells in mice who lack this molecule.
Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vinu Ninan, MD 909 Frostwood Dr Ste 1.100, Houston, TX 77024-2301 Ph: (713) 338-5519 | Vinu Ninan, MD 14023 Southwest Fwy, Sugar Land, TX 77478-3550 Ph: (281) 325-4100 |
News Archive
Across the nation, states are grappling with alternative approaches to address the heightened problem of low nurse staffing in hospitals.
In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.
QLT Inc. announced today that its board of directors has approved the repurchase of up to 3,622,495 common shares of QLT, representing 10% of the public float, over the next 12 months on the NASDAQ Stock Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), pending required approvals.
One single molecule determines how stem cells in the hair follicle develop. A study at the Sahlgrenska Academy at Göteborg University in Sweden has shown that cells that should give rise to hair can instead give rise to mammary gland cells in mice who lack this molecule.
Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
› Verified 1 days ago
Monica Kalra, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14023 Southwest Fwy, Sugar Land, TX 77478 Phone: 281-325-4100 | |
Dr. Brent Devin Reed, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15200 Southwest Fwy Ste 175, Sugar Land, TX 77478 Phone: 713-461-2915 Fax: 713-461-5307 | |
Robbyn Lucille Traylor, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2415 Town Center Dr, Ste 300, Sugar Land, TX 77478 Phone: 281-201-0657 | |
Dr. Cedela Abdulla, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3533 Town Center Blvd S, Ste. 200, Sugar Land, TX 77479 Phone: 713-772-0793 Fax: 281-781-2557 | |
Wyntria Lacabe-moore, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1403 Highway 6, Sugar Land, TX 77478 Phone: 832-260-0640 | |
Dr. Abraham K. Peringol, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 14815 Southwest Fwy, Sugar Land, TX 77478 Phone: 281-565-2140 Fax: 281-565-2174 | |
Owen Capocyan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4911 Sandhill Dr, Sugar Land, TX 77479 Phone: 816-334-9302 |